BioSafety Systems
This article was originally published in The Gray Sheet
Executive Summary
San Diego, California-based firm files registration statement with the Securities and Exchange Commission for an initial public offering of 500,000 shares of common stock at a proposed price of $6 per share. The manufacturer of products to minimize the occupational risks of health care workers expects to net $2.5 mil from the offering, of which 56% (1.4 mil.) will be used for "working capital purposes." Remaining proceeds are to be used to retire debt and fund the "expansion of its marketing activities," according to the prospectus. Upon completion of the offering, BioSafety will have 2.8 mil. shares of common stock outstanding. Underwriting the offering are Stonegate Securities and Cullum & Sandow Securities. BioSafety has three product lines: Chemo-Safety Products to protect pharmacists and nurses from exposure to cytotoxic drugs; P2 Infection Control Products to protect against blood-borne pathogens; and Respiratory Safety Products to minimize the risk due to airborne tuberculosis bacteria and chemicals such as pentamidine and ribavirin. Sales of the products generated revenues of $11.1 mil. in the year ended June 30, while net earnings were $1 mil.
You may also be interested in...
Could Eledon’s Anti-CD40L Change Transplant Medicine?
Eledon Pharmaceuticals’ CD40 Ligand blocker has yielded impressive results for post-transplant immunosuppression and cutting-edge transplant doctors have also used it for pig-to-human kidney and heart transplants, opening up the field of xenotransplantation.
Turning That Frown Upside Down: Treating Depression With Facial Botox Injections
In this episode of the In Vivo podcast, Eric Finzi, CEO of Healis Therapeutics, discusses how his company is targeting major depression, post-traumatic stress disorder and other mental illnesses using facial botox injections.
California Bill To Age-Restrict Sales Of Diet Pills Further Along Than Other States’ Legislation
CA, MA and NJ legislatures remain in session with bills active proposing regulations similar to NY law effective 22 April requiring retailers, including online, to ask for proof of age when customers buying consumer health products containing ingredients labeled or promoted for weight loss and bodybuilding benefits appear younger than 18.